Statin therapy may reduce cirrhosis and its decompensation in CHB patients
Statin therapy may reduce the risk of cirrhosis and its associated comorbidities in chronic hepatitis B (CHB) patients, according to a presentation at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017 held in Shanghai, China.
“Statins reduce cirrhosis and its decompensation in CHB patients independent of baseline comorbidity index and severity of liver disease,” said the researchers led by Dr Yi-Wen Huang from the Liver Center at Cathay General Hospital Medical Center in Taipei, Taiwan.
Statin therapy independently protected against cirrhosis (adjusted hazard ratio [adjHR], 0.133, 95 percent confidence interval [CI], 0.091–0.194; p<0.01) and decompensated cirrhosis (adjHR, 0.143, 95 percent CI, 0.100–0.206; p<0.01) in CHB patients after adjusting for potential confounders, medication use, and certain comorbidities such as hypertension, diabetes, hyperlipidaemia, obesity and nonalcoholic fatty liver disease. [APASL 2017, abstract PP 0052]
Hepatocellular carcinoma, hepatic coma, ascites, and use of aspirin and glucose- and lipid-lowering medications were notable risk factors associated with cirrhosis and decompensated cirrhosis.
Using data from the Taiwanese Health Insurance Research Database from 1997 to 2009, researchers conducted a population-based cohort study on 18,993 CHB patients. Statin users (≥28 cumulative defined daily doses [cDDD] per year) and nonstatin (<28 cDDD per year) users were identified and followed up until the progression of cirrhosis and its decompensation or until December 2009 or insurance withdrawal.
The findings were consistent with those of a previous study that established a dose-dependent reduction in the risk of cirrhosis and decompensated cirrhosis in CHB patients undergoing statin therapy. [Am J Gastroenterol 2016;doi:10.1038/ajg.2016.179]